NCT03616834 2023-03-22Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor TherapyEffector TherapeuticsPhase 2 Completed39 enrolled
NCT03258398 2019-07-18A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal CancerEffector TherapeuticsPhase 2 Completed56 enrolled